CN104684557A - 逆转录酶抑制剂的晶形 - Google Patents

逆转录酶抑制剂的晶形 Download PDF

Info

Publication number
CN104684557A
CN104684557A CN201380050220.9A CN201380050220A CN104684557A CN 104684557 A CN104684557 A CN 104684557A CN 201380050220 A CN201380050220 A CN 201380050220A CN 104684557 A CN104684557 A CN 104684557A
Authority
CN
China
Prior art keywords
compound
oxo
methyl
base
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380050220.9A
Other languages
English (en)
Chinese (zh)
Inventor
C.K.马圭尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Priority to CN201811295039.5A priority Critical patent/CN109384765A/zh
Publication of CN104684557A publication Critical patent/CN104684557A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380050220.9A 2012-09-26 2013-09-20 逆转录酶抑制剂的晶形 Pending CN104684557A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811295039.5A CN109384765A (zh) 2012-09-26 2013-09-20 逆转录酶抑制剂的晶型

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705780P 2012-09-26 2012-09-26
US61/705780 2012-09-26
PCT/US2013/060787 WO2014052171A1 (en) 2012-09-26 2013-09-20 Crystalline form of a reverse transcriptase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201811295039.5A Division CN109384765A (zh) 2012-09-26 2013-09-20 逆转录酶抑制剂的晶型

Publications (1)

Publication Number Publication Date
CN104684557A true CN104684557A (zh) 2015-06-03

Family

ID=50388877

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380050220.9A Pending CN104684557A (zh) 2012-09-26 2013-09-20 逆转录酶抑制剂的晶形
CN201811295039.5A Pending CN109384765A (zh) 2012-09-26 2013-09-20 逆转录酶抑制剂的晶型

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201811295039.5A Pending CN109384765A (zh) 2012-09-26 2013-09-20 逆转录酶抑制剂的晶型

Country Status (9)

Country Link
US (1) US9150539B2 (https=)
EP (1) EP2900240B1 (https=)
JP (2) JP6387349B2 (https=)
CN (2) CN104684557A (https=)
BR (1) BR112015005997A8 (https=)
CA (1) CA2882947A1 (https=)
ES (1) ES2773105T3 (https=)
MX (1) MX362517B (https=)
WO (1) WO2014052171A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2930585A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Process for making reverse transcriptase inhibitors
US11077050B2 (en) 2017-03-24 2021-08-03 Merck Sharp & Dohme Corp. Formulation for parenteral administration
IL294108A (en) * 2019-12-20 2022-08-01 Epizyme Inc Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222134A1 (en) * 2004-04-02 2005-10-06 Boehringer Ingelheim International Gmbh Crystalline forms of 5, 11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepin-6-one
US20110245296A1 (en) * 2010-03-30 2011-10-06 Jason Burch Non-nucleoside reverse transcriptase inhibitors
WO2011126969A1 (en) * 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Prodrugs of an hiv reverse transcriptase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006010545A1 (en) * 2004-07-27 2006-02-02 F. Hoffmann-La Roche Ag Benzyltriazolone compounds as non-nucleoside reverse transcriptase inhibitors
BRPI0811988B1 (pt) * 2007-05-30 2021-05-25 F. Hoffmann-La Roche Ag Composto intermediário e processo para preparação de triazolonas
CN101952274A (zh) * 2007-11-20 2011-01-19 默沙东公司 非核苷逆转录酶抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222134A1 (en) * 2004-04-02 2005-10-06 Boehringer Ingelheim International Gmbh Crystalline forms of 5, 11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2',3'-e] [1,4]diazepin-6-one
US20110245296A1 (en) * 2010-03-30 2011-10-06 Jason Burch Non-nucleoside reverse transcriptase inhibitors
WO2011126969A1 (en) * 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Prodrugs of an hiv reverse transcriptase inhibitor

Also Published As

Publication number Publication date
US9150539B2 (en) 2015-10-06
MX362517B (es) 2019-01-21
JP2015531372A (ja) 2015-11-02
ES2773105T3 (es) 2020-07-09
CN109384765A (zh) 2019-02-26
US20150232447A1 (en) 2015-08-20
JP2018024683A (ja) 2018-02-15
WO2014052171A1 (en) 2014-04-03
EP2900240B1 (en) 2020-01-08
EP2900240A1 (en) 2015-08-05
BR112015005997A8 (pt) 2023-04-11
EP2900240A4 (en) 2016-07-13
BR112015005997A2 (pt) 2017-07-04
JP6387349B2 (ja) 2018-09-05
CA2882947A1 (en) 2014-04-03
MX2015003767A (es) 2015-07-14

Similar Documents

Publication Publication Date Title
TWI877197B (zh) Ｃｆｔｒ調節劑之結晶形式
DK1910370T3 (en) PYRIDINQUINOLINE SUBSTITUTED PYRROLO [1,2-B] PYRAZOLE MONOHYDRATE AS TGF-BETA INHIBITOR
CN105209437B (zh) 心肌肌球蛋白激动剂的盐和制备盐的方法
TW201617347A (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法
AU2015330554B2 (en) Crystal form of bisulfate of JAK inhibitor and preparation method therefor
WO2015103456A1 (en) Crystalline forms of afatinib di-maleate
CN110678178A (zh) Mk2抑制剂的形式和组合物
WO2018109786A1 (en) Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
JP2012517990A (ja) 結晶質の多形性形態６３１
CN104684557A (zh) 逆转录酶抑制剂的晶形
KR20130103483A (ko) Ｎ-［2-［［(2,3-디플루오로페닐)메틸］티오］-6-｛［(1ｒ,2ｓ)-2,3-디히드록시-1-메틸프로필］옥시｝-4-피리미디닐］-1-아제티딘술폰아미드의 신규 결정질 형태
EP3430004A1 (en) Solid state forms of nilotinib salts
WO2016172333A1 (en) A solid state form of perampanel
WO2014193865A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5- d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
US20250034129A1 (en) CRYSTALLINE FORMS OF (6S,7S)-6-FLUORO-7-(2-FLUORO-5-METHYLPHENYL)-3-(TETRAHYDRO-2H-PYRAN-4-YL)-5,6,7,8-TETRAHYDROPYRIDO[2,3-d]PYRIMIDINE-2,4(1H,3H)-DIONE
JP2021533111A (ja) Ｌｔａ４ｈ阻害剤の結晶形態
US20250074934A1 (en) Crystal of 4’-substituted nucleoside, and preparation method therefor, composition thereof and use thereof
CN101611024A (zh) 芳基-取代的吡唑-酰胺化合物的晶形
TW202412788A (zh) (6S,7S)-6-氟-7-(2-氟-5-甲基苯基)-3-(四氫-2H-哌喃-4-基)-5,6,7,8-四氫吡啶并[2,3-d]嘧啶-2,4(1H,3H)-二酮之晶型
WO2017079678A1 (en) Solid state forms of a pde10 inhibitor
WO2023134769A1 (zh) 4'-取代核苷的晶体、其制备方法、组合物和用途
WO2023222103A1 (zh) 一种三嗪二酮类衍生物的晶型及制备方法
CN121773096A (zh) 4-氯-5-[4-(2,6-二氯苯基)磺酰基哌嗪-1-基]-1-苯并呋喃-2-甲酸的l-赖氨酸盐及其各种形式
TW202602874A (zh) Akt1抑制劑及其鹽之固態形式
CN121646582A (zh) 4-氯-5-[4-(2,6-二氯苯基)磺酰基哌嗪-1-基]-1-苯并呋喃-2-甲酸的氨丁三醇盐及其各种形式

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150603

RJ01 Rejection of invention patent application after publication